FDA Approves Beacon Biosignals’ AI-Assisted Sleep Monitoring Device
Dreem 3S to implement electroencephalogram data from the brain to monitor sleep architecture.
Beacon Biosignals revealed that they have been approved for the FDA 510(k) clearance on the Dreem 3S, its wearable headband with integrated machine learning algorithms to capture electroencephalogram (EEG) data from the brain to monitor sleep architecture and aid in the diagnosis of disturbed sleep. The approval comes amid Beacon Biosignals’ acquisition of Dreem this past June.
"Longitudinal EEG sleep data may be a powerful tool to gain clinical insight into a wide variety of neurological and psychiatric conditions,” said Jacob Donoghue, MD, PhD, CEO, co-founder, Beacon Biosignals. “We are enabling high-fidelity, overnight brain activity to be efficiently collected in the patient's home, opening new doors for clinical trial endpoints."
Reference: Beacon Biosignals Receives FDA Clearance for AI-Assisted Sleep Monitoring Device Dreem 3S. PR Newswire. September 14, 2023. Accessed September 14, 2023. https://www.prnewswire.com/news-releases/beacon-biosignals-receives-fda-clearance-for-ai-assisted-sleep-monitoring-device-dreem-3s-301927727.html#:~:text=BOSTON%2C%20Sept.%2014%2C%202023,monitor%20sleep%20architecture%20and%20aid
New machine-learning approach could speed precision drug development
The approach, detailed this week in the journal Nature, uses a platform called Molecular Surface Interaction Fingerprinting (MaSIF) to design custom proteins that bind to drug-bound target proteins.
AI-enabled CGM app shows promise for glycemic control, weight management
The broader implications of this study suggest that digital health platforms like January V2 have the potential to play a crucial role in the future of chronic disease management,” the authors write.
